• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600530.SS
Share

Shanghai Jiaoda Onlly Co.,Ltd Stocks

CN¥ 3.92Last Updated 04.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 449.37M

CN¥ 3.92
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Low dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai Jiaoda Onlly Co., Ltd., together with its various subsidiaries, primarily operates within China's health food sector. The company's product portfolio is extensive, featuring functional health items, probiotics, traditional tonics, dietary supplements, and natural extracts, alongside a range of disinfection solutions. Beyond health-related products, the firm is also engaged in the wholesale and retail distribution of pharmaceutical goods, as well as the production and sale of other food products. Further diversifying its operations, Shanghai Jiaoda Onlly provides road cargo and transportation services, in addition to offering travel agency activities. Headquartered in Shanghai, China, this company was founded in 1990.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.09.2026 19:26

Trump, defying "hawkish" signals from the labor market, demanded that the Fed cut interest rates

04.09.2026 18:56

New Arguments in Favor of the "Hawks": Strong Employment Data Pushed the Dow Jones Down

04.09.2026 17:41

U.S. job growth in August was three times higher than expected. What will the Fed decide?

04.09.2026 17:18

The Dollar Faces a Triple Threat: Interest Rates, the Yen, and Hedging

04.09.2026 16:27

Where to invest $1,000 in autumn 2026: Three small-cap ideas from Freedom

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026